All Updates

All Updates

icon
Filter
Funding
Hexagon Bio raises USD 77.3 million Series B
AI Drug Discovery
Feb 13, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 13, 2023

Hexagon Bio raises USD 77.3 million Series B

Funding

  • California-based AI drug discovery startup, Hexagon Bio, has raised USD 77.3 million in a Series B funding round which saw participation from existing investors, The Column Group and Two Sigma Ventures, as well as new investors, including Canada Pension Plan Investment Board (CPP Investments). 

  • The proceeds will be directed toward expanding its team across various fields and enhancing the capabilities of its drug discovery platform. 

  • Founded in 2016, Hexagon Bio engages in the discovery of medicines based on the global metagenome—a collection of the genetic material of all the microorganisms present in various ecosystems such as soil, water, and the human body. It leverages its proprietary platform that combines AI/ML technologies, genomics, chemistry, and synthetic biology to accelerate drug-target prediction, DNA sequencing, and compound production.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.